HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Post-Switch Market Exclusivity Benefits Everyone, Insists Global Switch Expert

Executive Summary

Three- to five-year market exclusivity periods for switched products would not only incentivize consumer healthcare firms but also enable pre- and post-switch data to be generated more easily, thus improving the quality of switch applications, explains global switch expert Dr Natalie Gauld in the final part of our exclusive interview. 

You may also be interested in...



Are Rx-To-OTC Switches Worth The Trouble? Yes They Are, IQVIA Data Shows

The holy grail of consumer health innovation, Rx-to-OTC switches, are costly and hard to pull off. So, are they worth the effort? An analysis by IQVIA of desloratadine, which was switched in Germany 2020 by Novartis subsidiary, Hexal, shows that they are, with sales of OTC desloratadine products growing 112% between 2019 and 2020. 

Norway Model Offers Key To Unlock More Complex Switches

Norway's move to encourage more innovative Rx-to-OTC switches has begun to bear fruit with the recent reclassification of Pfizer's Viagra. The country's decision to introduce a new non-prescription drug category to promote switching can be used as a model for securing a new wave of more complex switches elsewhere around the world.

Global Industry Welcomes World Health Organization’s Call For Widespread Oral Contraceptive Rx-To-OTC Switch

The Global Self-Care Industry Federation (previously the WSMI) welcomes a call from the World Health Organization to make oral contraceptive pills available OTC.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS149019

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel